$PGNX Recent News Progenics prices offering at 5.2%

New Post Public Reply Private Reply Replies (0) Message Board

Jun 13, 2014 at 11:55 PM

$PGNX Recent News

Progenics prices offering at 5.2% discount 12:02 p.m. Nov. 29, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 4:15 p.m. July 30, 2012 - MarketWatch
Progenics, Salix shares hit by FDA rejection 11:29 a.m. July 30, 2012 - Val Brickates Kennedy
Progenics, Salix tumble on FDA drug rejection 10:46 a.m. July 30, 2012 - Val Brickates Kennedy
Tuesday’s biggest gaining and declining stocks 5:58 p.m. Dec. 20, 2011 - Val Brickates Kennedy
Drug stocks up as OSI rejects $3.5 billion bid 4:32 p.m. March 15, 2010 - Kate Gibson
Wyeth, Progenics: Phase 3 trial of Relistor misses endpoints 7:05 a.m. May 22, 2008 - Michelle Donley
Wyeth, Progenics get Canadian approval for Relistor 7:09 a.m. April 1, 2008 - Michael Kitchen
Monday's biggest gaining and declining stocks 2:07 p.m. March 17, 2008 - MarketWatch
U.S. stocks close lower as record high crude weighs 4:38 p.m. March 12, 2008 - Nick Godt
Drug stocks gain; Progenics plunges on failed study 3:46 p.m. March 12, 2008 - Val Brickates Kennedy
U.S. stock futures steady to lower after big run-up 9:16 a.m. March 12, 2008 - Steve Goldstein
Wyeth delayed on trade errors; Momenta shares slump 1:13 p.m. June 28, 2007 - Val Brickates Kennedy
Progenics, Wyeth report positive methylnaltrexone study 5:10 a.m. June 28, 2007 - Steve Goldstein
Progenics, Wyeth say 'positive' Methylnaltrexone study 5:07 a.m. June 28, 2007 - Steve Goldstein
Biotech, pharma rise; Vertex slips on earnings 12:01 p.m. May 1, 2007 - Val Brickates Kennedy
Progenics, Wyeth submit NDA for methylnaltrexone formula 5:08 a.m. March 30, 2007 - Sarah Turner
Progenics, Wyeth to submit NDA for methylnaltrexone formula 5:01 a.m. March 30, 2007 - Sarah Turner
U.S. markets poised to retest major support 10:14 a.m. March 14, 2007 - Michael Ashbaugh
Biotech, pharma benchmarks fall; CV Therapeutics dives 5:18 p.m. March 7, 2007 - Val Brickates Kennedy

Two Undervalued Biopharmas to Buy Now 2:46 p.m. Today - Barrons.com
Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 9.23% - Tale of the Tape 8:44 a.m. Today - Zacks.com
Progenics schedules conference call to discuss Ad Comm recommendation 6:06 p.m. June 12, 2014 - Seeking Alpha
Ad Comm recommendation bodes well for opioid-induced constipation drugs 12:54 p.m. June 12, 2014 - Seeking Alpha
Progenix trading halted while Ad Comm meets 8:28 a.m. June 11, 2014 - Seeking Alpha
Progenics Pharmaceuticals (PGNX) in Focus: Stock Falls 5.5% - Tale of the Tape 8:49 a.m. June 5, 2014 - Zacks.com
The IBB Likely To Move Higher Along With These Biotechs With Catalysts Upcoming 8:30 a.m. June 2, 2014 - Seeking Alpha
Progenics Pharma Poised For A Potential Price Increase Ahead Of June 11 Adcom 8:30 a.m. May 30, 2014 - Seeking Alpha
2nd Half Of 2014 Biotechnology Catalysts: Part 1 9:34 a.m. May 27, 2014 - Seeking Alpha
Nektar Therapeutics: The Time Is Nigh 11:57 a.m. May 19, 2014 - Seeking Alpha
Progenics' Q1 Loss Narrows - Analyst Blog 11:10 a.m. May 15, 2014 - Zacks.com
Salix Q1 Earnings Boosted by Santarus Acquisition - Analyst Blog 1:41 p.m. May 9, 2014 - Zacks.com
Progenics Pharmaceuticals' (PGNX) CEO Mark Baker on Q1 2014 Results - Earnings Call Transcript 12:31 p.m. May 9, 2014 - Seeking Alpha
10-Q: PROGENICS PHARMACEUTICALS INC 10:42 a.m. May 9, 2014 - Edgar Online - (EDG = 10Q, 10K)
Progenics Pharmaceuticals (PGNX) Q1 2014 Results - Earnings Call Webcast 8:25 a.m. May 9, 2014 - Seeking Alpha
Progenics Finishes Patient Enrollment - Analyst Blog 7:00 p.m. April 25, 2014 - Zacks.com
Progenics Pharmaceuticals Announces Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC 9:17 a.m. April 24, 2014 - benzinga.com
EMA considers Relistor label expansion 12:21 p.m. April 23, 2014 - Seeking Alpha
Salix Pharmaceuticals, Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand Use of RELISTORby the European Medicines Agency 6:02 a.m. April 22, 2014 - benzinga.com
First Week Of PGNX November 22nd Options Trading 11:58 a.m. March 26, 2014 - TheStreet.com

Progenics Schedules Investor Conference Call Following FDA Advisory Committee 3:41 p.m. June 12, 2014 - GlobeNewswire
FDA Ad Comm Provides Recommendations Regarding the Potential Cardiovascular Risk Associated with the Class of Peripherally-active Opioid Receptor Antagonists and the Trials to Support Approval of Products for OIC 2:32 p.m. June 12, 2014 - BusinessWire - BZX
Progenics Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Consider and Provide Recommendations Regarding Peripherally-Acting Opioid Receptor Antagonists 7:06 a.m. June 11, 2014 - GlobeNewswire
Technical Analysis on Biotech Equities -- Research on Incyte, Progenics Pharma, Immunomedics, and Arqule 7:30 a.m. June 5, 2014 - PR Newswire - PRF
Progenics Pharmaceuticals CEO Mark Baker to Present at Jefferies Global Healthcare Conference 2:31 p.m. June 2, 2014 - GlobeNewswire
Progenics Pharmaceuticals' PSMA ADC Data Selected for Poster Highlight Presentation at ASCO 2014 8:01 a.m. May 30, 2014 - GlobeNewswire
Stocks Analysis on Top Gainers -- Research on Progenics Pharma, Lionbridge Technologies, Nuverra Environmental Solutions, and Senomyx 11:30 a.m. May 12, 2014 - PR Newswire - PRF
Progenics Pharmaceuticals Announces First Quarter 2014 Financial Results 7:31 a.m. May 9, 2014 - GlobeNewswire
Progenics Pharmaceuticals Sets First Quarter 2014 Financial Results Call for May 9 7:31 a.m. May 1, 2014 - GlobeNewswire
Earnings Schedules, Acquisition Agreements, and Financial Results Release - Analyst Notes on Mallinckrodt, BioMarin, Salix Pharmaceuticals, St. Jude Medical and Quest Diagnostics 8:00 a.m. April 25, 2014 - PR Newswire - PRF
Progenics Pharmaceuticals Announces the Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC 10:18 a.m. April 24, 2014 - GlobeNewswire
Salix Pharmaceuticals and Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand the Use of RELISTOR in Chronic Non-Cancer Pain by the European Medicines Agency 7:02 a.m. April 22, 2014 - BusinessWire - BZX
Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications 12:36 p.m. April 1, 2014 - GlobeNewswire
Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa 8:00 a.m. March 21, 2014 - PR Newswire - PRF
Top Gainers Ahead of Market -- Research on Genco Shipping & Trading, Progenics Pharma, Rambus, and Exact Sciences 8:05 a.m. March 19, 2014 - PR Newswire - PRF
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2013 Financial Results and Initiates Clinical Development of Small Molecule Targeted Therapeutic 9:02 a.m. March 13, 2014 - GlobeNewswire
Progenics Pharmaceuticals Sets 4Q and Year-End 2013 Financial Results Call for March 13 1:48 p.m. March 10, 2014 - GlobeNewswire
Progenics Pharmaceuticals Sets 1Q 2014 Financial Results Call for March 13 1:00 p.m. March 4, 2014 - GlobeNewswire
DryShips Braces for More Losses in Slowly Recovering Economy 10:34 a.m. Feb. 24, 2014 - ACCESSWIRE
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock 10:00 a.m. Feb. 21, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...